424 A phase 1b/2 randomized study of AVB-S6–500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatmentKathryn E. Beckermann, Eric Jonasch, Mao Shifeng et al.|Regular and Young Investigator Award Abstracts|2021Cited by 2